Waters (WAT) 8-K Sales of $714 million grew 5% as reported and 10% in constant currency

Exhibit 99.1

For Immediate Release

Contact:    Caspar Tudor, Head of Investor Relations – (508) 482-2429

Waters Corporation (NYSE: WAT) Reports Second Quarter 2022 Financial Results

Highlights

• Sales of $714 million grew 5% as reported and 10% in constant currency

• Continued strong momentum as instrument sales grew 12% in constant currency, with double-digit growth across LC, MS and TA product lines

• Broad-based performance across all end-markets and major geographies, led by mid-teens growth in the U.S. and 9% constant currency growth in China

• Recurring revenues grew high-single-digits as strong commercial execution continued

• GAAP EPS of $2.72; non-GAAP EPS of $2.75, a 6% increase from prior year

Milford, Mass., August 2, 2022—Waters Corporation (NYSE: WAT) today announced its financial results for the second quarter of 2022.

“Our team’s strong focus on execution continued to deliver excellent results, despite the challenging macroeconomic environment, with instrument sales growing 12% and recurring revenues growing 8% in constant currency in the second quarter. The sustained commercial momentum and broad-based growth in each of our regions reflects continued strong customer demand across the attractive growth markets that we serve,” said Dr. Udit Batra, President and Chief Executive Officer of Waters Corporation.

Dr. Batra continued, “Our rejuvenated portfolio continues to capture growth opportunities in both large and small molecule applications, with Arc^TM HPLC, ACQUITY^TM Premier, and MaxPeak^TM Premier columns again providing a strong contribution to growth in the quarter. Meanwhile, we are increasingly well-positioned to support the workflows of more complex molecules as they move downstream through process development and into high-volume applications. With the recent release of the Xevo^TM G3 Q-TOF and new applications on waters_connect^TM, we are continuously adding new capabilities to enhance the characterization and quantitation of biologics and novel modalities.”

Second Quarter 2022

Sales for the second quarter of 2022 were $714 million, an increase of 5% as reported and 10% in constant currency, compared to sales of $682 million for the second quarter of 2021.

On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2022 was $2.72, compared to $2.69 for the second quarter of 2021. On a non-GAAP basis, EPS increased by 6% to $2.75, compared to $2.60 for the second quarter of 2021. This includes a headwind of approximately 11% due to unfavorable foreign currency translation.

During the second quarter of 2022, sales into the pharmaceutical market increased 5% as reported and 10% in constant currency, sales into the industrial market increased 3% as reported and 8% in constant currency and sales into the academic and government markets increased 10% as reported and 16% in constant currency.

During the quarter, instrument system sales increased 7% as reported and 12% in constant currency, while recurring revenues, which represent the combination of service and precision chemistries, increased 3% as reported and 8% in constant currency.

Geographically, sales in Asia during the quarter increased 3% as reported and 9% in constant currency (with China sales growing 9%), sales in the Americas increased 14% as reported and 15% in constant currency (with U.S. sales growing 14%) and sales in Europe decreased 4% as reported and increased 7% in constant currency.

First Half 2022

Sales for the first half of 2022 were $1,405 million, an increase of 9% as reported and 13% in constant currency, compared to sales of $1,290 million for the first half of 2021.

On a GAAP basis, EPS for the first half of 2022 increased to $5.35, compared to $5.05 for the first half of 2021. On a non-GAAP basis, EPS increased by 13% to $5.55, compared to $4.89 in the first half of 2021.

For the first half of 2022, sales into the pharmaceutical market increased 10% as reported and 14% in constant currency, sales into the industrial market increased 8% as reported and 12% in constant currency and sales into the academic and government markets increased 5% as reported and 10% in constant currency.

For the first half of 2022, instrument system sales increased 15% as reported and 19% in constant currency, while recurring revenues increased 4% as reported and 9% in constant currency.

Geographically, sales in Asia for the first half of 2022 increased 7% as reported and 11% in constant currency (with China sales growing 13%), sales in the Americas increased 20% (with U.S. sales growing 21%) and sales in Europe decreased 1% as reported and increased 8% in constant currency.

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant currency growth rates in the tables below.

A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website www.waters.com in the Investor Relations section.

Full-Year and Third Quarter 2022 Financial Guidance

The Company is raising its full-year 2022 guidance, and now expects constant currency sales growth in the range of 9.5% to 10.5%. Currency translation is expected to decrease full-year sales growth by approximately five percentage points. The Company is reaffirming the mid-point of its full-year 2022 non-GAAP EPS guidance with an updated range of $11.95 to $12.05, which includes an estimated headwind of approximately 9% due to unfavorable foreign currency translation. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year.

The Company expects third quarter 2022 constant currency sales growth in the range of 8% to 10%. Currency translation is expected to decrease third quarter sales growth by approximately six percentage points. The Company expects third quarter 2022 non-GAAP EPS in the range of $2.50 to $2.60, which includes an estimated headwind of approximately 10% due to unfavorable foreign currency translation. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the third quarter.

Conference Call

Waters Corporation will webcast its second quarter 2022 financial results conference call today, August 2, 2022 at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select “Investors” under the “About Waters” section, navigate to “Events & Presentations,” and click on the “Webcast.” A replay will be available through at least August 16, 2022 at midnight Eastern Time on the same website by webcast and also by phone at (800) 685-6061.

About Waters Corporation

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and adjusted free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these

non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to the effects of the ongoing COVID-19 pandemic on our business, financial condition, results of operations and prospects, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or other reasons related to the pandemic, increased risks of cyber-attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain and distribution network, volatility and uncertainty in global capital markets limiting our ability to access capital, customers being unable to make timely payments for purchases and volatility in demand for our products; foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products, including delays or disruptions to our distribution network, among the Company’s various market sectors or geographies from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom exiting the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; shifts in taxable income in jurisdictions with different

effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, including any potential impact on the Company’s operations stemming from sustained inflation, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights; and the impact and costs of war, in particular as a result of the ongoing conflict between Russia and Ukraine, and the possibility of further escalation resulting in a new geopolitical and regulatory instability. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2021, as well as in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” of the Company’s quarterly report on Form 10-Q for the quarterly period ended April 2, 2022, as filed with the Securities and Exchange Commission (“SEC”), which discussions are incorporated by reference in this release, as updated by the Company’s future filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Arc, ACQUITY, MaxPeak, Xevo, and waters_connect are trademarks of Waters Corporation.

Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

	Three Months Ended						Six Months Ended
	July 2, 2022			July 3, 2021			July 2, 2022			July 3, 2021
Net sales	$	714,319		$	681,647		$	1,404,891		$	1,290,192
Costs and operating expenses:
Cost of sales		307,206			280,254			592,891			534,401
Selling and administrative expenses		161,877			158,213			319,352			301,409
Research and development expenses		44,006			44,949			84,478			83,041
Purchased intangibles amortization		1,598			1,809			3,271			3,649
Acquired in-process research and development		—			—			9,797			—
Operating income		199,632			196,422			395,102			367,692
Other income, net (a)		1,535			9,321			1,705			18,680
Interest expense, net		(8,893	)		(8,329	)		(17,838	)		(15,174	)
Income from operations before income taxes		192,274			197,414			378,969			371,198
Provision for income taxes		27,410			30,122			54,274			55,779
Net income	$	164,864		$	167,292		$	324,695		$	315,419
Net income per basic common share	$	2.74		$	2.71		$	5.38		$	5.09
Weighted-average number of basic common shares		60,206			61,685			60,399			61,979
Net income per diluted common share	$	2.72		$	2.69		$	5.35		$	5.05
Weighted-average number of diluted common shares and equivalents		60,510			62,157			60,744			62,435

(a) During the three and six months ended July 3, 2021, the Company executed a settlement agreement to resolve patent infringement litigation with Bruker Corporation and Bruker Daltronik GmbH regarding their timsTOF product line. In connection with the settlement, the Company is entitled to receive $10 million in guaranteed payments, including minimum royalty payments, which was recognized within Other income, net in our consolidated statement of operations. During the six months ended July 3, 2021, the Company recorded an unrealized gain of $10 million due to an observable change in the fair value of an existing investment the Company does not have the ability to exercise significant influence over.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Three Months Ended July 2, 2022 and July 3, 2021

(In thousands)

	Three Months Ended				Percent			Current Period Currency			Constant Currency
	July 2, 2022		July 3, 2021		Change			Impact			Growth Rate (a)
NET SALES - OPERATING SEGMENTS
Waters	$	635,152	$	607,324		5	%	$	(32,871	)		10	%
TA		79,167		74,323		7	%		(3,750	)		12	%
Total	$	714,319	$	681,647		5	%	$	(36,621	)		10	%
NET SALES - PRODUCTS & SERVICES
Instruments	$	337,683	$	314,496		7	%	$	(15,681	)		12	%
Service		244,689		240,692		2	%		(14,640	)		8	%
Chemistry		131,947		126,459		4	%		(6,300	)		9	%
Total Recurring		376,636		367,151		3	%		(20,940	)		8	%
Total	$	714,319	$	681,647		5	%	$	(36,621	)		10	%
NET SALES - GEOGRAPHY
Asia	$	278,010	$	269,947		3	%	$	(15,887	)		9	%
Americas		257,271		224,894		14	%		(418	)		15	%
Europe		179,038		186,806		(4	%)		(20,316	)		7	%
Total	$	714,319	$	681,647		5	%	$	(36,621	)		10	%
NET SALES - MARKETS
Pharmaceutical	$	437,171	$	416,705		5	%	$	(22,114	)		10	%
Industrial		208,517		202,579		3	%		(10,793	)		8	%
Academic & Government		68,631		62,363		10	%		(3,714	)		16	%
Total	$	714,319	$	681,647		5	%	$	(36,621	)		10	%
NET SALES - EXCLUDING CHINA
Total Net Sales	$	714,319	$	681,647		5	%	$	(36,621	)		10	%
China Net Sales		138,740		127,225		9	%		(508	)		9	%
Total Net Sales Excluding China	$	575,579	$	554,422		4	%	$	(36,113	)		10	%

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Six Months Ended July 2, 2022 and July 3, 2021

(In thousands)

	Six Months Ended				Percent			Current Period Currency			Constant Currency
	July 2, 2022		July 3, 2021		Change			Impact			Growth Rate (a)
NET SALES - OPERATING SEGMENTS
Waters	$	1,248,308	$	1,149,202		9	%	$	(48,727	)		13	%
TA		156,583		140,990		11	%		(5,331	)		15	%
Total	$	1,404,891	$	1,290,192		9	%	$	(54,058	)		13	%
NET SALES - PRODUCTS & SERVICES
Instruments	$	662,905	$	577,544		15	%	$	(21,969	)		19	%
Service		484,421		467,215		4	%		(22,803	)		9	%
Chemistry		257,565		245,433		5	%		(9,286	)		9	%
Total Recurring		741,986		712,648		4	%		(32,089	)		9	%
Total	$	1,404,891	$	1,290,192		9	%	$	(54,058	)		13	%
NET SALES - GEOGRAPHY
Asia	$	532,344	$	499,489		7	%	$	(23,458	)		11	%
Americas		506,108		422,251		20	%		(419	)		20	%
Europe		366,439		368,452		(1	%)		(30,181	)		8	%
Total	$	1,404,891	$	1,290,192		9	%	$	(54,058	)		13	%
NET SALES - MARKETS
Pharmaceutical	$	852,943	$	776,853		10	%	$	(33,272	)		14	%
Industrial		417,914		385,852		8	%		(14,946	)		12	%
Academic & Government		134,034		127,487		5	%		(5,840	)		10	%
Total	$	1,404,891	$	1,290,192		9	%	$	(54,058	)		13	%
NET SALES - EXCLUDING CHINA
Total Net Sales	$	1,404,891	$	1,290,192		9	%	$	(54,058	)		13	%
China Net Sales		259,772		230,144		13	%		342			13	%
Total Net Sales Excluding China	$	1,145,119	$	1,060,048		8	%	$	(54,400	)		13	%

(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Three and Six Months Ended July 2, 2022 and July 3, 2021

(In thousands, except per share data)

	Selling & Administrative Expenses(a)			Acquired IPR&D and Research & Development Expenses			Operating Income		Operating Income Percentage			Other Income (Expense)			Income from Operations before Income Taxes			Provision for Income Taxes			Net Income			Diluted Earnings per Share
Three Months Ended July 2, 2022
GAAP	$	163,475		$	44,006		$	199,632		27.9	%	$	1,535		$	192,274		$	27,410		$	164,864		$	2.72
Adjustments:
Purchased intangibles amortization (b)		(1,598	)		—			1,598		0.2	%		—			1,598			366			1,232			0.02
Restructuring costs and certain other items (d)		(1,830	)		—			1,830		0.3	%		(1,818	)		12			(5	)		17			—
Certain income tax items (f)		—			—			—		—			—			—			(506	)		506			0.01
Adjusted Non-GAAP	$	160,047		$	44,006		$	203,060		28.4	%	$	(283	)	$	193,884		$	27,265		$	166,619		$	2.75
Three Months Ended July 3, 2021
GAAP	$	160,022		$	44,949		$	196,422		28.8	%	$	9,321		$	197,414		$	30,122		$	167,292		$	2.69
Adjustments:
Purchased intangibles amortization (b)		(1,809	)		—			1,809		0.3	%		—			1,809			411			1,398			0.02
Restructuring costs and certain other items (d)		(614	)		—			614		0.1	%		—			614			44			570			0.01
Litigation settlement (e)		—			—			—		—			(10,083	)		(10,083	)		(1,916	)		(8,167	)		(0.13	)
Certain income tax items (f)		—			—			—		—			—			—			(594	)		594			0.01
Adjusted Non-GAAP	$	157,599		$	44,949		$	198,845		29.2	%	$	(762	)	$	189,754		$	28,067		$	161,687		$	2.60
Six Months Ended July 2, 2022
GAAP	$	322,623		$	94,275		$	395,102		28.1	%	$	1,705		$	378,969		$	54,274		$	324,695		$	5.35
Adjustments:
Purchased intangibles amortization (b)		(3,271	)		—			3,271		0.2	%		—			3,271			749			2,522			0.04
Acquired in-process research and development (c)		—			(9,797	)		9,797		0.7	%		—			9,797			2,351			7,446			0.12
Restructuring costs and certain other items (d)		(4,205	)		—			4,205		0.3	%		(2,234	)		1,971			456			1,515			0.02
Certain income tax items (f)		—			—			—		—			—			—			(994	)		994			0.02
Adjusted Non-GAAP	$	315,147		$	84,478		$	412,375		29.4	%	$	(529	)	$	394,008		$	56,836		$	337,172		$	5.55
Six Months Ended July 3, 2021
GAAP	$	305,058		$	83,041		$	367,692		28.5	%	$	18,680		$	371,198		$	55,779		$	315,419		$	5.05
Adjustments:
Purchased intangibles amortization (b)		(3,649	)		—			3,649		0.3	%		—			3,649			825			2,824			0.05
Restructuring costs and certain other items (d)		(1,484	)		—			1,484		0.1	%		(9,707	)		(8,223	)		(2,076	)		(6,147	)		(0.10	)
Litigation settlement (e)		—			—			—		—			(10,083	)		(10,083	)		(1,916	)		(8,167	)		(0.13	)
Certain income tax items (f)		—			—			—		—			—			—			(1,144	)		1,144			0.02
Adjusted Non-GAAP	$	299,925		$	83,041		$	372,825		28.9	%	$	(1,110	)	$	356,541		$	51,468		$	305,073		$	4.89

(a) Selling & administrative expenses include purchased intangibles amortization, litigation provisions and settlements and asset impairments.

(b) The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c) Acquired in-process research and development was excluded as it relates to the cost of a licensing arrangement for charge detection mass spectrometry that the Company believes is unusual and not indicative of its normal business operations.

(d) Restructuring costs, mergers and acquisition costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, acquire companies and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(e) Litigation settlement gains and provisions were excluded as these items are isolated, unpredictable and not expected to recur regularly.

(f) Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management’s assessment of ongoing examinations or other tax items that are not indicative of the Company’s normal or future income tax expense.

Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)

	July 2, 2022		December 31, 2021
Cash, cash equivalents and investments	$	419,794	$	569,285
Accounts receivable		639,451		612,648
Inventories		409,922		356,095
Property, plant and equipment, net		545,813		547,913
Intangible assets, net		225,101		242,401
Goodwill		428,005		437,865
Other assets		372,484		328,725
Total assets	$	3,040,570	$	3,094,932
Notes payable and debt	$	1,484,374	$	1,513,870
Other liabilities		1,164,072		1,213,508
Total liabilities		2,648,446		2,727,378
Total stockholders’ equity		392,124		367,554
Total liabilities and stockholders’ equity	$	3,040,570	$	3,094,932

Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Six Months Ended July 2, 2022 and July 3, 2021

(In thousands and unaudited)

	Three Months Ended						Six Months Ended
	July 2, 2022			July 3, 2021			July 2, 2022			July 3, 2021
Cash flows from operating activities:
Net income	$	164,864		$	167,292		$	324,695		$	315,419
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation		9,789			7,291			20,722			15,596
Depreciation and amortization		34,227			33,387			66,891			64,743
Change in operating assets and liabilities and other, net		(151,902	)		(64,930	)		(157,370	)		(34,314	)
Net cash provided by operating activities		56,978			143,040			254,938			361,444
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization		(39,269	)		(37,386	)		(67,020	)		(76,889	)
(Investments in) proceeds from equity investments, net		(1,139	)		—			5,646			—
Payments for intellectual property licenses		—			(7,000	)		(4,897	)		(7,000	)
Net change in investments		21,739			(77,716	)		66,594			(197,217	)
Net cash (used in) provided by investing activities		(18,669	)		(122,102	)		323			(281,106	)
Cash flows from financing activities:
Net change in debt		40,000			(100,000	)		(30,000	)		246,363
Proceeds from stock plans		18,082			28,741			30,914			45,036
Purchases of treasury shares		(151,808	)		(168,202	)		(321,944	)		(341,507	)
Other cash flow from financing activities, net		10,956			2,495			10,849			1,917
Net cash used in financing activities		(82,770	)		(236,966	)		(310,181	)		(48,191	)
Effect of exchange rate changes on cash and cash equivalents		(16,712	)		(7,699	)		(27,417	)		(8,786	)
(Decrease) increase in cash and cash equivalents		(61,173	)		(223,727	)		(82,337	)		23,361
Cash and cash equivalents at beginning of period		480,070			683,783			501,234			436,695
Cash and cash equivalents at end of period	$	418,897		$	460,056		$	418,897		$	460,056
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)
Net cash provided by operating activities - GAAP	$	56,978		$	143,040		$	254,938		$	361,444
Adjustments:
Additions to property, plant, equipment and software capitalization		(39,269	)		(37,386	)		(67,020	)		(76,889	)
Tax reform payments		38,454			38,454			38,454			38,454
Litigation settlements received		—			(3,367	)		(584	)		(3,367	)
Major facility renovations		11,112			13,795			17,039			28,285
Free Cash Flow - Adjusted Non-GAAP	$	67,275		$	154,536		$	242,827		$	347,927

(a) The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

Waters Corporation and Subsidiaries

Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook

	Three Months Ended							Twelve Months Ended
	October 1, 2022							December 31, 2022
	Range							Range
Projected Sales
Projected constant currency sales growth rate (a)		8.0	%	-		10.0	%		9.5	%	-		10.5	%
Projected currency impact		(6.0	%)	-		(6.0	%)		(5.0	%)	-		(5.0	%)
Projected sales growth rate as reported		2.0	%	-		4.0	%		4.5	%	-		5.5	%
Projected Earnings Per Diluted Share	Range							Range
Projected GAAP earnings per diluted share	$	2.48		-	$	2.58		$	11.71		-	$	11.81
Adjustments:
Purchased intangibles amortization	$	0.02		-	$	0.02		$	0.08		-	$	0.08
Acquired in-process research and development	$	—			$	—		$	0.12			$	0.12
Restructuring costs and certain other items	$	—		-	$	—		$	0.02		-	$	0.02
Certain income tax items	$	—		-	$	—		$	0.02		-	$	0.02
Projected adjusted non-GAAP earnings per diluted share	$	2.50		-	$	2.60		$	11.95		-	$	12.05

(a) Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.

These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.